212 related articles for article (PubMed ID: 17979736)
1. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
Vogel CW; Fritzinger DC
Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
[TBL] [Abstract][Full Text] [Related]
2. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
3. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
4. Structure and function of recombinant cobra venom factor.
Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
[TBL] [Abstract][Full Text] [Related]
5. Recombinant cobra venom factor.
Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
[TBL] [Abstract][Full Text] [Related]
6. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
[TBL] [Abstract][Full Text] [Related]
8. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
[TBL] [Abstract][Full Text] [Related]
9. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.
Vogel CW; Fritzinger DC
Toxicon; 2010 Dec; 56(7):1198-222. PubMed ID: 20417224
[TBL] [Abstract][Full Text] [Related]
10. Molecular isoforms of cobra venom factor-like proteins in the venom of Austrelaps superbus.
Rehana S; Manjunatha Kini R
Toxicon; 2007 Jul; 50(1):32-52. PubMed ID: 17412383
[TBL] [Abstract][Full Text] [Related]
11. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.
Vogel CW; Finnegan PW; Fritzinger DC
Mol Immunol; 2014 Oct; 61(2):191-203. PubMed ID: 25062833
[TBL] [Abstract][Full Text] [Related]
12. Methionine modification impairs the C5-cleavage function of cobra venom factor-dependent C3/C5 convertase.
Fu Q; McPhie P; Gowda DC
Biochem Mol Biol Int; 1998 Jun; 45(1):133-44. PubMed ID: 9635137
[TBL] [Abstract][Full Text] [Related]
13. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning and derived primary structure of cobra venom factor.
Fritzinger DC; Bredehorst R; Vogel CW
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12775-9. PubMed ID: 7809120
[TBL] [Abstract][Full Text] [Related]
15. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents.
Fritzinger DC; Hew BE; Lee JQ; Newhouse J; Alam M; Ciallella JR; Bowers M; Gorsuch WB; Guikema BJ; Stahl GL; Vogel CW
Adv Exp Med Biol; 2008; 632():293-307. PubMed ID: 19025130
[TBL] [Abstract][Full Text] [Related]
16. The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.
Krishnan V; Ponnuraj K; Xu Y; Macon K; Volanakis JE; Narayana SV
Structure; 2009 Apr; 17(4):611-9. PubMed ID: 19368894
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of Cobra Venom Factor/human C3 chimeras transiently expressed in mammalian cells.
Kölln J; Matzas M; Jänner N; Mix T; Klensang K; Bredehorst R; Spillner E
Mol Immunol; 2004 May; 41(1):19-28. PubMed ID: 15140572
[TBL] [Abstract][Full Text] [Related]
18. Structural studies on the cobra venom factor: isolation, purification, crystallization and preliminary crystallographic analysis.
Sharma S; Jabeen T; Singh RK; Bredhorst R; Vogel CW; Betzel C; Singh TP
Acta Crystallogr D Biol Crystallogr; 2001 Apr; 57(Pt 4):596-8. PubMed ID: 11264593
[TBL] [Abstract][Full Text] [Related]
19. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje.
Van den Berg CW; Aerts PC; Van Dijk H
J Immunol Methods; 1991 Feb; 136(2):287-94. PubMed ID: 1999656
[TBL] [Abstract][Full Text] [Related]
20. Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury.
Gorsuch WB; Guikema BJ; Fritzinger DC; Vogel CW; Stahl GL
Mol Immunol; 2009 Dec; 47(2-3):506-10. PubMed ID: 19747734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
